OCUL
NASDAQ HealthcareOcular Therapeutix, Inc. - Common Stock
Biotechnology
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
�� 市场数据
| 价格 | $9.82 |
|---|---|
| 成交量 | 5,316,554 |
| 市值 | 2.14B |
| 贝塔系数 | 0.950 |
| RSI（14日） | 72.7 超买 |
| 200日均线 | $11.10 |
| 50日均线 | $8.82 |
| 52周最高 | $16.44 |
| 52周最低 | $6.23 |
| Forward P/E | -7.82 |
| Price / Book | 3.24 |
🎯 投资策略评分
OCUL 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (72/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 💰 Dividend Daddy (35/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 OCUL in your text
粘贴任何文章、记录或帖子 — 工具将提取 OCUL 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.